# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Zelda Fitzgerald (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET004-SYN
- Date: 2026-10-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margot Ellery, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month review: maintenance treatment, lithium monitoring, and movement check. **S**

## History of present illness

Ms. Fitzgerald returns six weeks after her preventive visit, about six months after the episode. She has had no manic, depressive, or psychotic symptoms. She takes lithium 300 mg twice daily and aripiprazole 10 mg daily. The intrauterine system has caused only light spotting. Her HPV, HIV, hepatitis C, chlamydia and gonorrhea tests from the preventive visit were all negative. She dances about four hours a day, has a full rest day each week, eats to plan, and her periods remain regular. She sleeps eight hours and has finished a short story. She asks whether she will need both medicines for life. She has had no thoughts of suicide or self-harm. **S**

| Element | Detail |
|---|---|
| Mood and psychosis | No symptoms; PHQ-9 3 |
| Medicines | Lithium 300 mg twice daily; aripiprazole 10 mg daily; levonorgestrel intrauterine system |
| Results from the preventive visit | HPV, HIV, hepatitis C, chlamydia and gonorrhea tests negative |
| Dance and periods | About four hours a day with a rest day; periods regular |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight up slightly as planned |
| Genitourinary | Negative | Light spotting only; no pelvic pain; no increased urination |
| Neurological | Negative | Faint tremor when tired; no restlessness or abnormal movements |
| Psychiatric | Negative | Mood steady; no manic or psychotic symptoms; no thoughts of suicide or self-harm |

4 systems reviewed. **S**

## Current medications

- Lithium carbonate 300 mg oral capsule, one capsule by mouth twice daily **S**
- Aripiprazole 10 mg oral tablet, one tablet by mouth once daily **S**
- Folic acid 0.4 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 110/70 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 99% on room air; weight 52.4 kg; BMI 19.2 kg/m². All vital signs are synthetic.

Sodium: 139 mmol/L; Potassium: 4 mmol/L; Creatinine: 0.79 mg/dL; eGFR: 103 mL/min/1.73 m²; Lithium (12-hour trough): 0.72 mmol/L; TSH: 3.1 mIU/L; PHQ-9: 3. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4 mmol/L at baseline, 4 mmol/L at this visit **S**
- Creatinine: 0.72 mg/dL at baseline, 0.79 mg/dL at this visit **S**
- eGFR: 116 mL/min/1.73 m² at baseline, 103 mL/min/1.73 m² at this visit **S**
- TSH: 2.1 mIU/L at baseline, 3.1 mIU/L at this visit **S**
- PHQ-9: 11 at baseline, 3 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 52.4 kg, BMI 19.2; blood pressure 110/70, pulse 68 |
| Neck | Thyroid not enlarged |
| Neurological | AIMS score 0: no abnormal movements of the face, lips, jaw, tongue, limbs, or trunk; faint fine postural tremor; no akathisia |
| Psychiatric | Euthymic and engaged; organized; no psychotic or manic features |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Bipolar I disorder with psychotic features, in full remission** (F31.74). Remission for about four months. Lithium 0.72 mmol/L; creatinine 0.79 mg/dL, eGFR 103; TSH 3.1 mIU/L, within range and slightly higher than at baseline. After a first manic episode with psychosis, lithium is continued for the long term to prevent recurrence; the antipsychotic can often be tapered slowly after six months or more of remission, with a written relapse plan. Safety reviewed: no thoughts of suicide or self-harm; the safety plan and psychiatric advance directive are current. **S**
   - Continue lithium carbonate 300 mg twice daily.
   - Continue aripiprazole 10 mg daily until Dr. Langford reviews a slow taper with her next month.
   - Lithium level, creatinine and TSH every three to six months; calcium, glucose, A1c and lipids yearly; AIMS in six months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Antipsychotic dose, adherence, and response | Every visit | Completed today | Aripiprazole 10 mg; full adherence; taper to be reviewed with psychiatry |
| Survey | Manic, depressive, and psychotic symptoms, and early warning signs | Every visit | Completed today | No manic, depressive, or psychotic symptoms |
| Examination | Akathisia, parkinsonism, and sedation | Every visit in the first months and after any dose change | Completed today | None |
| Examination | Abnormal Involuntary Movement Scale (AIMS) | Baseline, then every 6 months | Completed today | AIMS score 0 at six months; repeat in six months |
| Examination | Weight and BMI | Every visit for 6 months after starting or changing an antipsychotic (CMID: baseline, 4, 8, and 12 weeks, then quarterly) | Completed today | 52.4 kg (BMI 19.2), up 1.6 kg from intake as planned; quarterly from now |
| Examination | Blood pressure | Baseline, 12 weeks, then yearly | Completed today | 110/70 |
| Laboratory | Fasting glucose and A1c | Baseline, 12 weeks to 4 months, then yearly | Up to date | Normal at three months; next in a year |
| Laboratory | Fasting lipid panel | Baseline, 12 weeks to 4 months, then yearly | Up to date | Normal at three months; next in a year |
| Laboratory | Lithium level (12-hour trough) | 5 to 7 days after starting and after any change until stable, then every 3 to 6 months | Completed today | 0.72 mmol/L; every three to six months from now |
| Laboratory | Creatinine and eGFR on lithium | Baseline, every 2 to 3 months for 6 months, then every 6 to 12 months | Completed today | Creatinine 0.79 mg/dL, eGFR 103; sodium 139, potassium 4.0 mmol/L |
| Laboratory | TSH on lithium | Baseline, once or twice in the first 6 months, then every 6 to 12 months | Completed today | 3.1 mIU/L; every six to twelve months from now |
| Laboratory | Calcium on lithium | Baseline, then yearly | Up to date | Normal at three months; next in a year |
| Medication safety | Lithium side effects and sick-day rules | At the start and every visit | Completed today | Faint tremor only; sick-day plan current |
| Medication safety | Pregnancy prevention on lithium; valproate avoided | Before starting and at each visit until a reliable method is in place | Completed today | Levonorgestrel intrauterine system in place; folic acid daily |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodically | Completed today | PHQ-9 3, from 11 at intake: remission |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan and psychiatric advance directive current; the 988 Suicide & Crisis Lifeline in her phone |
| Self-management | Sleep | Every visit | Completed today | Eight hours at regular times |
| Self-management | Eating, exercise, and periods | Every visit while periods are absent or weight is low | Completed today | Periods regular; about four hours of dance a day with a rest day; SCOFF 0 at the preventive visit |
| Self-management | Coordinated specialty care engagement | Ongoing, for up to two to three years | Completed today | Therapist every two weeks; peer specialist monthly |

## Goal progress

- No manic, depressive or psychotic episode and no readmission through six months. Outcome by 2026-10-26: No episode and no admission; lithium and aripiprazole continued. **S**
- Lithium trough level 0.6 to 0.8 mmol/L with normal kidney and thyroid tests at six months. Outcome by 2026-10-26: Lithium 0.72 mmol/L; creatinine 0.79 mg/dL; TSH 3.1 mIU/L. **S**
- Periods return and prolactin is normal by three months. Outcome by 2026-08-10: Periods returned five weeks after the switch to aripiprazole; prolactin 14 ng/mL. **S**
- BMI at least 19, with food matched to her training, by six months. Outcome by 2026-10-26: BMI 19.2 at 52.4 kg, dancing about four hours a day. **S**
- PHQ-9 score below 5 by six months. Outcome by 2026-10-26: PHQ-9 3. **S**

## Guideline basis

- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018), CANMAT and ISBD (Bipolar Disorders)
- The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence (2023), Focus (American Psychiatric Publishing)
- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020), American Psychiatric Association (American Journal of Psychiatry)
- Consensus development conference on antipsychotic drugs and obesity and diabetes (2004), American Diabetes Association, American Psychiatric Association, AACE, and NAASO (Diabetes Care)
- Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026), National Institute of Mental Health
- U.S. Selected Practice Recommendations for Contraceptive Use, 2024 (2024), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Psychiatry review with Dr. Langford next month about a slow aripiprazole taper. Visits every three months with lithium level, creatinine, and TSH. Calcium, glucose, A1c, lipids, and the AIMS as scheduled. **S**

